Fig. 9: Anti-androgen treatment reduces the number of TAMs in the prostate.

a Graphic visualization of the study design: 10 untreated PCa patients and 10 PCa patients treated with the anti-androgen bicalutamide prior to prostatectomy were matched for Gleason pathology score, serum PSA level, age and TNM classification. b PCA visualization of the Kmean unsupervised cluster analysis. Group 1 and Group 2 classify patients in untreated and treated patients, respectively. Numerical data in Supplementary Table 3. P = 0.024, Pearson correlation test was used to calculate the p-value with a cutoff for significance of 0.05. c Quantification of the percentage of CD163+ TAMs in the entire population of HLA-DR+ and/or CD14+ cells in prostatectomy specimen of untreated and bicalutamide treated patients. Datapoints show individual patients and error bars show the s.e.m. p = 0.0968. Paired parametric Studentʼs t test was used to calculate the p-value with a cutoff for significance of 0.05. Source data are provided as a source datafile.